Sarepta Therapeutics Inc.

07/09/2020 | Press release | Distributed by Public on 07/09/2020 13:56

Open-Label Evaluation of Etelpirsen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial